Xeris Biopharma Holdings, Inc. (XERS) earnings date
Mar 10, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 12 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Mon, Mar 2, 2026 | before open | 61 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Thu, Mar 6, 2025 | before open | 65 | 8-K |
What they guided beta
| Q3 FY2026 | "XERIS BIOPHARMA REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS Total revenue increased 44% year-over-year to $107 million Recorlev net revenue increased 93% year-over-year to more than $71 million Raises full-year 2026 total revenue guidance to $395 million to $405 million Raises 2030 total revenue outlook to more than $1 billion, up from approximately $750 million Conference call and webcast today at 8:30 a.m. ET CHICAGO — November 5, 2026 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping " exhibit |
| Q3 FY2026 | "“As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030," said John Shannon, Chairman and Chief Executive Officer of Xeris." exhibit |
| Q3 FY2026 | "Given the strong momentum across Recorlev, Gvoke, and Keveyis, we are raising our full-year total revenue guidance to $395–$405 million.”" exhibit |
| Q3 FY2026 | "Xeris remains on track to initiate Cornerstone by year-end 2026, with topline data expected in late 2028 and potential approval and launch in 2030." exhibit |
| Q3 FY2026 | "Third U.S. Patent Granted for XP-8121: On October 6, 2026, the United States Patent and Trademark Office (USPTO) granted Xeris U.S. Patent No. 12,751,937, entitled “Stable Levothyroxine Compositions In Aprotic Polar Solvents,” which is expected to expire on October 19, 2043." exhibit |
| Q2 FY2026 | "XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81% year-over-year to approximately $57 million Tightens full-year 2026 total revenue guidance to $385 million to $390 million Conference call and webcast today at 8:30 a.m. ET CHICAGO, IL; August 6, 2026 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a" exhibit |
| Q2 FY2026 | ""The strategic investments we made for Recorlev earlier this year are gaining traction, and we expect their contribution to become increasingly meaningful as we move through the second half of 2026." exhibit |
| Q2 FY2026 | "We received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new Keveyis patent expected to extend intellectual property protection through at least 2039, reinforcing our long-term commitment to the primary periodic paralysis community." exhibit |
| Q2 FY2026 | "With a strong first half behind us, we are tightening our full-year guidance to $385–$390 million, reflecting our confidence in the team, the portfolio, and the trajectory of our business." Second Quarter 2026 Highlights Three months ended" exhibit |
| Q2 FY2026 | "Once granted, it is expected to provide intellectual property protection for Keveyis through at least 2039." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/XERS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/XERS
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/XERS/"><img src="https://veritasdata.dev/embed/XERS.svg" alt="XERS earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/XERS/)
Script
<script async src="https://veritasdata.dev/embed/XERS.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/XERS"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.